Codexis, Inc. CDXS
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -35.58%
- 1 year
- -35.19%
5D +0.17 (+18.08%)
- Market cap
- 115.08M
- Revenue (ttm)
- 64.45M
- Profit margin
- -96.35%
- EPS (ttm)
- -0.18
- Shares out
- 81.38M
- Forward P/E
- -7.14
- YTD return
- -35.58%
- 1-year return
- -35.19%
- Volume
- 913.30K
- Avg volume
- 911.27K
- Open
- 1.13
- Previous close
- 1.15
- Day's range
- 1.04 – 1.13
- 52-week range
- 0.90 – 2.98
- Beta
- 2.07
- Price target
- 7.17 (+582.5%)
Key statistics
- 50-day average
- 4.19
- 200-day average
- 3.43
- Enterprise value
- 381.27M
- Price / sales
- 6.23
- Price / book
- 5.47
- Revenue growth
- 38.30%
- Free cash flow
- -8.12M
- Total cash
- 90.25M
- Total debt
- 41.85M
- Return on equity
- -75.31%
- Short % of float
- 2.36%
Fundamental scorecard
8 of 25 checks passed on CDXS’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.25 | -0.29 | -0.04 | -16.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.26 | -0.32 | -0.06 | -23.08% |
| May 2, 2024 | Mar 1, 2024 | -0.17 | -0.16 | +0.01 | +5.88% |
| Feb 28, 2024 | Dec 1, 2023 | -0.16 | 0.02 | +0.18 | +112.50% |
| Nov 2, 2023 | Sep 1, 2023 | -0.32 | -0.26 | +0.06 | +18.75% |
| Aug 3, 2023 | Jun 1, 2023 | -0.21 | -0.17 | +0.04 | +19.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 15, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 4, 2024 | Benchmark | reit | — | Hold |
| Sep 20, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 29, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 19, 2024 | Benchmark | down | Buy | Hold |
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- codexis.com
News
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference Stephens & Co. Reiterates Overweight on Codexis, Maintains $5 Price Target
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
What Codexis (CDXS) Said on Its Q3 Earnings Call
Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates Codexis Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $19.262M Beat $18.720M Estimate
Codexis Affirms FY2026 Sales Guidance of $72.000M-$76.000M vs $73.882M Est
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Your note
Sign in to keep a note on CDXS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE VRE RAYMOND | Director | Stock Award(Grant) | Nov 6, 2024 | 47,846 |
| DORGAN BYRON L | Director | Stock Award(Grant) | Jun 10, 2024 | 223,581 |
| ERBEZ GEORGIA L | Chief Financial Officer | Stock Award(Grant) | Oct 9, 2024 | 50,000 |
| MARTINBOROUGH ESTHER | Director | Stock Award(Grant) | Jun 10, 2024 | 88,053 |
| MOORE ALISON | Chief Technology Officer | Stock Award(Grant) | Oct 9, 2024 | 148,696 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 24, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 10.78% | 8,770,000 | 43.24M | Sep 29, 2024 |
| Casdin Capital, LLC | 9.95% | 8,100,000 | 39.93M | Sep 29, 2024 |
| Blackrock Inc. | 8.50% | 6,915,734 | 34.09M | Sep 29, 2024 |
| FMR, LLC | 5.53% | 4,497,090 | 22.17M | Sep 29, 2024 |
| Vanguard Group Inc | 5.10% | 4,152,719 | 20.47M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.65% | 2,967,808 | 14.63M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.55% | 2,075,798 | 10.23M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.23% | 1,811,668 | 8.93M | Oct 30, 2024 |
| Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I | 1.56% | 1,267,085 | 6.25M | Jul 30, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 1.40% | 1,141,000 | 5.63M | Oct 30, 2024 |
| Fidelity Advisor Equity Growth Fund | 1.38% | 1,122,880 | 5.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.25% | 1,016,202 | 5.01M | Sep 29, 2024 |
